CINECA IRIS Institutional Research Information System

ROSSO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.411
NA - Nord America 14.616
EU - Europa 10.572
SA - Sud America 858
AF - Africa 387
OC - Oceania 284
Continente sconosciuto - Info sul continente non disponibili 15
Totale 42.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.664
CN - Cina 9.110
IT - Italia 2.232
DE - Germania 1.650
SG - Singapore 1.473
SE - Svezia 954
JP - Giappone 931
GB - Regno Unito 810
FR - Francia 808
IE - Irlanda 686
KR - Corea 612
IN - India 606
HK - Hong Kong 587
BR - Brasile 563
CA - Canada 557
ES - Italia 426
TR - Turchia 418
TW - Taiwan 369
NL - Olanda 365
MX - Messico 351
PL - Polonia 337
UA - Ucraina 325
AT - Austria 322
VN - Vietnam 313
FI - Finlandia 304
AU - Australia 264
ID - Indonesia 250
RU - Federazione Russa 232
EG - Egitto 218
DK - Danimarca 189
BE - Belgio 187
GR - Grecia 182
IR - Iran 129
RO - Romania 112
CZ - Repubblica Ceca 91
CH - Svizzera 84
IL - Israele 84
PT - Portogallo 80
PK - Pakistan 79
CO - Colombia 69
PE - Perù 61
TH - Thailandia 58
CL - Cile 55
SA - Arabia Saudita 55
AR - Argentina 54
IQ - Iraq 40
MY - Malesia 39
EC - Ecuador 38
PH - Filippine 36
MO - Macao, regione amministrativa speciale della Cina 34
NO - Norvegia 34
HU - Ungheria 30
UZ - Uzbekistan 25
BD - Bangladesh 21
LB - Libano 20
LT - Lituania 20
MA - Marocco 20
DZ - Algeria 18
NZ - Nuova Zelanda 16
RS - Serbia 16
AE - Emirati Arabi Uniti 15
GH - Ghana 15
SI - Slovenia 15
SK - Slovacchia (Repubblica Slovacca) 15
BG - Bulgaria 14
CM - Camerun 14
EU - Europa 14
JO - Giordania 13
NG - Nigeria 13
QA - Qatar 13
ZA - Sudafrica 13
HR - Croazia 12
MN - Mongolia 11
BF - Burkina Faso 9
BY - Bielorussia 9
LY - Libia 9
CY - Cipro 8
ET - Etiopia 8
LK - Sri Lanka 8
LU - Lussemburgo 8
PS - Palestinian Territory 8
VE - Venezuela 8
GE - Georgia 7
GT - Guatemala 7
KE - Kenya 7
KZ - Kazakistan 7
CR - Costa Rica 6
CU - Cuba 6
CV - Capo Verde 6
KG - Kirghizistan 6
PA - Panama 6
TN - Tunisia 6
LV - Lettonia 5
PR - Porto Rico 5
EE - Estonia 4
KH - Cambogia 4
MD - Moldavia 4
MZ - Mozambico 4
OM - Oman 4
PY - Paraguay 4
Totale 42.063
Salva come PNG Salva come JPEG
Città #
Beijing 1.325
Chandler 1.284
Ann Arbor 988
Singapore 896
Shanghai 764
Fairfield 760
Dublin 674
Santa Clara 647
Ashburn 590
Guangzhou 548
Houston 487
Redwood City 469
Woodbridge 385
Wilmington 367
Dearborn 348
Nanjing 342
Torino 323
Seattle 313
Hangzhou 295
Tokyo 261
Villeurbanne 256
Jacksonville 253
Wuhan 243
Cambridge 241
Nyköping 239
Vienna 234
Ottawa 231
Pisa 226
Turin 212
Chengdu 203
Medford 200
Taipei 199
Princeton 194
Columbus 187
Jinan 174
Dong Ket 172
Jakarta 159
Los Angeles 157
Hefei 156
Rome 155
New York 153
Seoul 153
Chongqing 148
Boston 139
Warsaw 138
Zhengzhou 129
Changsha 128
Hong Kong 128
Fremont 127
Central 126
London 119
Milan 114
Shenyang 110
Munich 103
San Diego 101
Tianjin 95
Istanbul 92
Toronto 86
Changchun 85
Helsinki 83
Sydney 83
Nanning 82
Frankfurt am Main 80
Brussels 76
Fuzhou 76
Delhi 75
Nuremberg 75
Kunming 73
Central District 72
Paris 68
Cairo 65
Athens 64
Boardman 63
Harbin 62
Washington 62
Hebei 61
Madrid 60
Nanchang 57
Xi'an 54
Berlin 53
Qingdao 53
San Jose 53
Copenhagen 52
Suzhou 52
Hanoi 50
São Paulo 50
Amsterdam 48
Ankara 48
Shenzhen 48
Xian 48
Norwalk 47
Santiago 47
Chicago 46
Stockholm 46
Mumbai 45
Newcastle upon Tyne 44
Düsseldorf 43
San Mateo 43
Barcelona 41
Pittsburgh 40
Totale 20.819
Salva come PNG Salva come JPEG
Nome #
Liver cancer: Connections with obesity, fatty liver, and cirrhosis 7.722
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 4.848
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.949
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 1.569
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 1.268
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 1.142
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 714
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease 692
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. 615
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 575
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 546
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 487
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 467
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 380
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 351
Endocrine manifestations of chronic HCV infection 337
Fecal calprotectin: beyond intestinal organic diseases 307
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 288
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 278
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 245
Liver fibrosis: the 2017 state of art 245
Physiopathology of intestinal barrier and the role of zonulin 224
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 214
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 209
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 196
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 194
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 190
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 190
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 188
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 184
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 183
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 181
How to diagnose NAFLD in 2016 179
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation 179
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 175
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 175
Non-alcoholic fatty liver disease and extra-hepatic cancers 173
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis 171
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 170
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study 168
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 166
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 164
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 162
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 161
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 161
Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test 152
Association Between Gut Permeability and Insulin Resistance: Any Role for Zonulin in Patients with Non-Alcoholic Fatty Liver Disease? 150
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease 150
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 147
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 146
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 145
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 145
Metabolic handling of an oral fat load in NAFLD patients. 143
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 142
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 141
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 140
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 139
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with Non Alcoholic Fatty Liver Disease independent of diabetes, hypertension and dyslipidemia 138
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 138
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 138
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 131
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 131
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 131
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 130
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 130
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 128
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 128
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 128
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 127
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 126
Basic and clinical aspects of resistin 126
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 125
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 124
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 124
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 123
Efficacy of a preparation based on calcium butyrate, bifidobacterium bifidum, bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study 123
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 119
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 119
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 117
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 117
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 117
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 116
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 116
Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease 114
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 112
Diagnostic accuracy of soluble sCD163 for the detection of severe fibrosis in patients with Non-Alcoholic Fatty Liver Disease 112
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease 111
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 110
Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience 110
Moving towards core antigen for the management of patients with overt and occult HBV infection 110
Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy 109
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C 108
Integrative hepatic transcriptome analysis identifies biomarkers of non-alcoholic steatohepatitis activity and fibrosis progression 108
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 107
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 107
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 107
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 106
Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease 106
Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis. 106
After oral fat load NAFLD subjects and healthy controls show different serum free fatty acid trends. 105
Totale 36.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.664
article - articoli 0
book - libri 0
conference - conferenze 28.006
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.670
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020587 0 0 0 0 0 0 0 0 0 0 294 293
2020/20215.413 342 439 365 380 545 442 456 355 524 505 457 603
2021/20226.055 312 353 406 522 494 420 599 556 630 471 767 525
2022/20236.351 534 483 305 515 535 1.021 562 455 654 357 427 503
2023/20246.746 617 689 638 620 651 679 465 672 178 456 520 561
2024/20258.077 485 642 618 772 1.446 828 622 618 911 733 402 0
Totale 43.105